STAT+: Pfizer to discontinue its GLP-1 pill for obesity due to liver toxicity
Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity.
Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with a different mechanism of action.
Pfizer said in a press release that an asymptomatic volunteer in the company’s studies experienced “potential drug-induced liver injury,” which resolved after stopping the medication. After reviewing all clinical data for the medicine and consulting with regulators, Pfizer decided to halt research on it.
“While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients,” said Chris Boshoff, Pfizer’s chief scientific officer and head of R&D, in a statement.
